Comparing cost-effectiveness of short-course regimens for drug-resistant tuberculosis treatment in India.

ABSTRACT:

Background

Short-course regimens are currently explored to improve multidrug-resistant tuberculosis effects, reduce costs, as well as enhance patient adherence. Currently, we are determining the most cost-effective shorter regimen out of seven short-course regimens (6-9 months) to treat drug-resistant tuberculosis (DR-TB) compared to the current standard of care (SoC) 9- to 11-month regimen.

Methods

Cost-effectiveness of various short-course DR-TB treatment regimens, namely BEAT, BPaL, BPaLM, BPaLC, mBPaL1, mBPaL2, and mBPaL3, was compared to the current SoC in India. Decision tree model was used from a health system perspective. The information on various costs - such as preinvestigations, regimens, adverse drug reactions (ADRs) management, inpatient treatment - and on effe

SUBMITTER: Muniyandi M 

PROVIDER: S-EPMC12322854 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature